DexCom, Inc. (DXCM)
Here's Why You Should Add DexCom Stock to Your Portfolio Now
DXCM continues to raise investor optimism due to its strong product portfolio.
Top Health & Fitness Stocks to Buy for the Wellness Boom
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that underscore its sustained momentum. The company's performance, driven by strong product demand, successful innovation, and strategic market access expansion, strongly supports an ambitious trajectory for the remainder of 2025, indicating a clear path towards further solidifying its leadership in diabetes technology.
5 Best Stocks of the S&P 500 ETF in the Past Month
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.
DexCom: Growth Is Reaccelerating But Don't Ignore The Risks
I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, establishing a reaccelerating trend in growth for the company. However, DXCM's competitor product, Abbott's Libre Freestyle, has been growing faster despite larger sales.
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
2 Growth Stocks to Buy and Hold for a Decade
Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock market. While it's a perfectly human reaction to volatility, it's a tendency investors should avoid.
DexCom, Inc. (DXCM) Q1 2025 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Sean Christensen - VP, Finance & IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, CFO & Chief Accounting Officer Jacob Leach - EVP & COO Conference Call Participants Matt Taylor - Jefferies Robbie Marcus - JPMorgan Danielle Antalffy - UBS Jeff Johnson - Baird Jayson Bedford - Raymond James Travis Steed - Bank of America Merrill Lynch Matt O'Brien - Piper Sandler Marie Thibault - BTIG Joanne Wuensch - Citibank Michael Polark - Wolfe Research Margaret Andrew - William Blair Mike Kratky - Leerink Partners Colin Clark - Stifel, Nicolaus & Company Issie Kirby - Redburn Bill Plovanic - Canaccord Chris Pasquale - Nephron Steve Lichtman - Oppenheimer & Co. Matt Miksic - Barclays Anthony Petrone - Mizuho Group Operator Welcome to the DexCom First Quarter 2025 Earnings Release Conference Call. My name is Louella, and I will be your operator for today's call.
Compared to Estimates, DexCom (DXCM) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DexCom (DXCM) Q1 Earnings Miss Estimates
DexCom (DXCM) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.32 per share a year ago.
